Last reviewed · How we verify
Desoximetasone Spray 0.25%
Desoximetasone is a topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.
Desoximetasone is a topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis).
At a glance
| Generic name | Desoximetasone Spray 0.25% |
|---|---|
| Also known as | Desoximetasone |
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Desoximetasone is a synthetic corticosteroid that penetrates skin tissue and binds to intracellular glucocorticoid receptors, leading to reduced production of inflammatory mediators, decreased immune cell infiltration, and suppression of local inflammatory responses. This results in reduced erythema, pruritus, and other signs of dermatological inflammation. The spray formulation allows for convenient topical application to affected areas.
Approved indications
- Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis)
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Folliculitis
Key clinical trials
- Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray (PHASE4)
- Topical Psoriasis Study for Patients Receiving Biologic Therapy (PHASE4)
- Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis (PHASE4)
- Evaluating Treatment Resistant Dermatitis TaroIIR (PHASE4)
- Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis (PHASE3)
- Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study (PHASE2)
- Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis (PHASE3)
- Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desoximetasone Spray 0.25% CI brief — competitive landscape report
- Desoximetasone Spray 0.25% updates RSS · CI watch RSS
- Sun Pharmaceutical Industries, Inc. portfolio CI